MX2007008980A - Acidos nucleicos para apoptosis de celulas cancerigenas. - Google Patents

Acidos nucleicos para apoptosis de celulas cancerigenas.

Info

Publication number
MX2007008980A
MX2007008980A MX2007008980A MX2007008980A MX2007008980A MX 2007008980 A MX2007008980 A MX 2007008980A MX 2007008980 A MX2007008980 A MX 2007008980A MX 2007008980 A MX2007008980 A MX 2007008980A MX 2007008980 A MX2007008980 A MX 2007008980A
Authority
MX
Mexico
Prior art keywords
seq
apoptosis
nucleic acids
cancer cells
nucleic acid
Prior art date
Application number
MX2007008980A
Other languages
English (en)
Inventor
Don Adams North
Original Assignee
Sky Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sky Genetics Inc filed Critical Sky Genetics Inc
Publication of MX2007008980A publication Critical patent/MX2007008980A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a un acido nucleico que tiene una Secuencia Apoptotica de la Sec. ID. No. 1, Sec. ID. No. 2, Sec. ID. No. 3, Sec. ID. No. 4, Sec. ID. No. 5, Sec. ID. No. 6 y Sec. ID. No. 7. Tambien se refiere a una composicion que incluye un acido nucleico que tiene una Secuencia Apoptotica de la Sec. ID. No. 1, Sec. ID. No. 2, Sec. ID. No. 3, Sec. ID. No. 4, Sec. ID. No. 5, Sec. ID. No. 6 y Sec. ID. No. 7. La composicion tambien puede incluir un portador farmaceuticamente aceptable. La descripcion tambien incluye un metodo para eliminar una celula cancerigena administrando a una celula cancerigena, un suero que incluye un acido nucleico que tiene una Secuencia Apoptotica de la Sec. ID. No. 1, Sec. ID. No. 2, Sec. ID. No. 3, Sec. ID. No. 4, Sec. ID. No. 5, Sec. ID. No. 6 y Sec. ID. No. 7 y un portador farmaceuticamente aceptable. El portador puede ser localizado en un sujeto con cancer.
MX2007008980A 2005-01-25 2005-12-19 Acidos nucleicos para apoptosis de celulas cancerigenas. MX2007008980A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64696105P 2005-01-25 2005-01-25
US66963905P 2005-04-08 2005-04-08
PCT/US2005/045903 WO2006081008A2 (en) 2005-01-25 2005-12-19 Nucleic acids for apoptosis of cancer cells

Publications (1)

Publication Number Publication Date
MX2007008980A true MX2007008980A (es) 2008-01-14

Family

ID=36740938

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007008980A MX2007008980A (es) 2005-01-25 2005-12-19 Acidos nucleicos para apoptosis de celulas cancerigenas.

Country Status (10)

Country Link
US (1) US20060194229A1 (es)
EP (1) EP1841866B1 (es)
JP (1) JP2008527996A (es)
KR (1) KR20070095452A (es)
AT (1) ATE429495T1 (es)
AU (1) AU2005325716A1 (es)
CA (1) CA2592562A1 (es)
DE (1) DE602005014148D1 (es)
MX (1) MX2007008980A (es)
WO (1) WO2006081008A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007121054A2 (en) * 2006-03-27 2007-10-25 Sky Genetics, Inc. Nucleic acids for apoptosis of cancer cells
US8822153B2 (en) * 2007-06-01 2014-09-02 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
WO2009131366A2 (ko) * 2008-04-21 2009-10-29 한국생명공학연구원 위암 또는 대장암 진단 마커 및 치료제로서의 cdca5
KR101166256B1 (ko) * 2008-04-21 2012-07-18 한국생명공학연구원 위암 또는 대장암 진단 마커 및 치료제로서의 cdca5
CA2740046A1 (en) * 2008-10-09 2010-04-15 British Columbia Cancer Agency Branch Detection of granulosa-cell tumors
WO2010042228A2 (en) * 2008-10-10 2010-04-15 Cornell University Methods for predicting disease outcome in patients with colon cancer
ES2700098T3 (es) * 2009-05-15 2019-02-14 Insight Genetics Inc Métodos relacionados con las fusiones de ALK para diagnosticar el cáncer
KR101441013B1 (ko) * 2011-06-30 2014-09-18 충남대학교산학협력단 유방암 진단용 바이오마커
BR112017006419A2 (pt) 2014-09-30 2017-12-19 Univ Washington medições cinéticas de tau
CN110331201B (zh) * 2019-07-26 2022-04-08 泗水县人民医院 宫颈鳞癌相关生物标志物及其应用
CN110904214B (zh) * 2019-12-13 2020-12-15 四川省人民医院 用于诊断或辅助诊断肾功能不全或肾损伤的诊断剂、试剂盒和应用
CN111118164A (zh) * 2020-03-02 2020-05-08 遵义市第一人民医院 一种用于肿瘤早期筛查和诊断的标志物、试剂盒及检测方法
CN111751529A (zh) * 2020-05-12 2020-10-09 陕西中医药大学 一种抽动障碍的血清多肽标志物p及其检测方法
CN116482367A (zh) * 2023-05-04 2023-07-25 中国中医科学院望京医院(中国中医科学院骨伤科研究所) 一种联合mSEPT9检测和生物标志物的结直肠癌检测方法
CN117051112B (zh) * 2023-10-12 2023-12-29 上海爱谱蒂康生物科技有限公司 生物标志物组合在制备预测淋巴瘤的试剂盒中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) * 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5800992A (en) * 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5527681A (en) * 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US6416952B1 (en) * 1989-06-07 2002-07-09 Affymetrix, Inc. Photolithographic and other means for manufacturing arrays
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6346413B1 (en) * 1989-06-07 2002-02-12 Affymetrix, Inc. Polymer arrays
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5064413A (en) * 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US6506558B1 (en) * 1990-03-07 2003-01-14 Affymetrix Inc. Very large scale immobilized polymer synthesis
US5386023A (en) * 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
DE69132905T2 (de) * 1990-12-06 2002-08-01 Affymetrix Inc N D Ges D Staat Detektion von Nukleinsäuresequenzen
US5412087A (en) * 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6027880A (en) * 1995-08-02 2000-02-22 Affymetrix, Inc. Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
US5861242A (en) * 1993-06-25 1999-01-19 Affymetrix, Inc. Array of nucleic acid probes on biological chips for diagnosis of HIV and methods of using the same
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US6156501A (en) * 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
US5429807A (en) * 1993-10-28 1995-07-04 Beckman Instruments, Inc. Method and apparatus for creating biopolymer arrays on a solid support surface
AU2360195A (en) * 1994-05-05 1995-11-29 Beckman Instruments, Inc. Oligonucleotide repeat arrays
US5556752A (en) * 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US6239273B1 (en) * 1995-02-27 2001-05-29 Affymetrix, Inc. Printing molecular library arrays
US5624711A (en) * 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5545531A (en) * 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US6022963A (en) * 1995-12-15 2000-02-08 Affymetrix, Inc. Synthesis of oligonucleotide arrays using photocleavable protecting groups
US6013440A (en) * 1996-03-11 2000-01-11 Affymetrix, Inc. Nucleic acid affinity columns
US6255071B1 (en) * 1996-09-20 2001-07-03 Cold Spring Harbor Laboratory Mammalian viral vectors and their uses
US6025192A (en) * 1996-09-20 2000-02-15 Cold Spring Harbor Laboratory Modified retroviral vectors
WO1998020967A1 (en) * 1996-11-14 1998-05-22 Affymetrix, Inc. Chemical amplification for the synthesis of patterned arrays
US6887665B2 (en) * 1996-11-14 2005-05-03 Affymetrix, Inc. Methods of array synthesis
US6833450B1 (en) * 2000-03-17 2004-12-21 Affymetrix, Inc. Phosphite ester oxidation in nucleic acid array preparation
US6806361B1 (en) * 2000-03-17 2004-10-19 Affymetrix, Inc. Methods of enhancing functional performance of nucleic acid arrays
US6949638B2 (en) * 2001-01-29 2005-09-27 Affymetrix, Inc. Photolithographic method and system for efficient mask usage in manufacturing DNA arrays
WO2005054517A2 (en) * 2003-12-01 2005-06-16 Epigenomics Ag Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders
US20080026410A1 (en) * 2004-12-02 2008-01-31 Antonia Vlahou Biomarkers for Bladder Cancer
US20060183893A1 (en) * 2005-01-25 2006-08-17 North Don A Nucleic acids for apoptosis of cancer cells

Also Published As

Publication number Publication date
US20060194229A1 (en) 2006-08-31
DE602005014148D1 (de) 2009-06-04
CA2592562A1 (en) 2006-08-03
EP1841866B1 (en) 2009-04-22
EP1841866A2 (en) 2007-10-10
AU2005325716A1 (en) 2006-08-03
WO2006081008A3 (en) 2006-12-14
ATE429495T1 (de) 2009-05-15
KR20070095452A (ko) 2007-09-28
WO2006081008A2 (en) 2006-08-03
JP2008527996A (ja) 2008-07-31

Similar Documents

Publication Publication Date Title
MX2007008980A (es) Acidos nucleicos para apoptosis de celulas cancerigenas.
MX2008007286A (es) Ingenieria in vivo de superficie celular.
WO2006018836A3 (en) Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
IL213613A (en) History of pirazine, preparations containing them and their uses
WO2010048552A3 (en) Methods of using oligomeric compounds comprising 2'-substituted nucleosides
YU44404A (sh) Postupak za identifikovanje ciljnih enzima tumora
EA201070030A1 (ru) Синтез и применение антиинвертированных фосфоротиоатных аналогов кэп-структуры матричной phk
CN101687915B8 (zh) 跨物种特异性CD3-ε结合结构域
IL144703A0 (en) Methods and reagents for treating glucose metabolic disorders
EP1483281A4 (en) METHOD FOR THE PRODUCTION OF INTERFERING RNA MOLECULES IN MAMMALIAN CELLS AND THERAPEUTIC APPLICATIONS OF SUCH MOLECULES
UA92157C2 (ru) Способ продуцирования гормона роста
WO2006017134A3 (en) Preprimitive streak and mesendoderm cells
NZ584893A (en) PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
WO2008070666A3 (en) Compositions and methods to treat cancer with cpg rich dna and cupredoxins
WO2009151907A3 (en) Compositions and methods for using cells to treat heart tissue
WO2008042686A3 (en) Multifunctional carriers for the delivery of nucleic acids and methods of use thereof
WO2006010070A3 (en) Compositions and methods related to peptides that selectively bind leukemia cells
WO2006065894A3 (en) Methods for inhibiting stat3 signaling in immune cells
WO2006097743A3 (en) Method for actvating natural killer cells by tumor cell preparation in vitro
MX2009002787A (es) Composiciones y métodos para prevenir el cáncer con cupredoxinas.
WO2004062602A3 (en) Compositions and methods for targeted biological delivery of molecular carriers
SG10201407944TA (en) Imp-3 oligopeptides and vaccines including the same
WO2005120588A3 (en) Peptides delivered to cell nuclei
WO2003070905A3 (en) Electroporation methods for introducing bioactive agents into cells

Legal Events

Date Code Title Description
FA Abandonment or withdrawal